



Diabetes Medications		
BAQSIMI® (glucagon) nasal powder; Basaglar® (insulin glargine injection); Glucagon (glucagon for injection [rDNA origin]); Humalog® (insulin lispro injection); Humulin® (human insulin); Lyumjev™ (insulin lispro-aabc injection); Trulicity® (dulaglutide)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$220,000	37
AL	\$16,900,000	2513
AR	\$4,600,000	573
AZ	\$6,800,000	881
CA	\$17,200,000	2371
CO	\$3,400,000	442
CT	\$1,900,000	262
DC	\$170,000	25
DE	\$1,700,000	225
FL	\$41,200,000	5898
GA	\$32,600,000	4604
HI	\$300,000	47
IA	\$4,000,000	497
ID	\$4,400,000	623
IL	\$17,600,000	2182
IN	\$29,000,000	3475
KS	\$11,300,000	1539
KY	\$10,000,000	1289
LA	\$9,800,000	1328
MA	\$4,700,000	586
MD	\$7,900,000	998
ME	\$3,900,000	527
MI	\$21,100,000	2571
MN	\$7,500,000	989
MO	\$21,400,000	2806
MS	\$8,000,000	1125
MT	\$1,800,000	246
NC	\$52,900,000	6949
ND	\$1,000,000	129
NE	\$8,100,000	1153
NH	\$3,700,000	408
NJ	\$7,700,000	1058
NM	\$1,400,000	208
NV	\$3,200,000	441
NY	\$13,400,000	1712
OH	\$37,900,000	4627
OK	\$10,800,000	1588
OR	\$8,600,000	896
PA	\$24,100,000	3125
PR	\$140,000	28
RI	\$2,700,000	315
SC	\$13,300,000	1851
SD	\$1,500,000	222
TN	\$24,900,000	3295
TX	\$85,900,000	11925
UT	\$7,900,000	968
VA	\$26,000,000	3463
VI	\$19,000	2
VT	\$310,000	48
WA	\$5,900,000	710
WI	\$12,600,000	1579
WV	\$5,100,000	668
WY	\$1,500,000	203

Lyumjev™ is a trademark and BAQSIMI®, Basaglar®, Humalog®, Humulin®, and Trulicity® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.



Mental Health Medications		
Cymbalta® (duloxetine delayed-release capsules); Prozac® (fluoxetine); Strattera® (atomoxetine); Symbyax® (olanzapine and fluoxetine); Zyprexa® (olanzapine)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AL	\$3,800,000	1009
AR	\$150,000	51
AZ	\$74,000	23
CA	\$280,000	81
CO	\$150,000	33
CT	\$40,000	9
DE	\$34,000	7
FL	\$6,200,000	1639
GA	\$8,900,000	2004
HI	\$16,000	2
IA	\$74,000	20
ID	\$610,000	169
IL	\$290,000	91
IN	\$1,100,000	288
KS	\$3,100,000	653
KY	\$360,000	99
LA	\$310,000	91
MA	\$33,000	13
MD	\$240,000	61
ME	\$450,000	106
MI	\$370,000	112
MN	\$200,000	55
MO	\$3,000,000	712
MS	\$1,100,000	291
MT	\$230,000	57
NC	\$10,500,000	2290
ND	\$140,000	21
NE	\$2,700,000	552
NH	\$120,000	32
NJ	\$200,000	47
NM	\$14,000	5
NV	\$35,000	12
NY	\$290,000	51
OH	\$830,000	193
OK	\$13,500,000	2810
OR	\$220,000	59
PA	\$790,000	199
PR	\$1,000	1
RI	\$26,000	6
SC	\$1,400,000	315
SD	\$2,200,000	424
TN	\$3,500,000	752
TX	\$43,600,000	9378
UT	\$230,000	61
VA	\$4,000,000	939
WA	\$130,000	40
WI	\$380,000	83
WV	\$230,000	71
WY	\$760,000	157

Cymbalta®, Prozac®, Strattera®, Symbyax®, and Zyprexa® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.



Cancer Medications		
Alimta® (pemetrexed for injection); Cyramza® (ramucirumab); Erbitux® (cetuximab); Portrazza® (necitumumab); Retevmo® (selpercatinib); Verzenio® (abemaciclib)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$130,000	1
AL	\$4,600,000	113
AR	\$2,700,000	49
AZ	\$4,700,000	105
CA	\$12,900,000	215
CO	\$3,600,000	57
CT	\$1,800,000	44
DC	\$61,000	1
DE	\$470,000	7
FL	\$25,500,000	500
GA	\$8,900,000	165
HI	\$320,000	9
IA	\$1,200,000	21
ID	\$1,600,000	25
IL	\$5,300,000	102
IN	\$4,900,000	81
KS	\$2,200,000	65
KY	\$2,700,000	45
LA	\$1,400,000	29
MA	\$3,100,000	50
MD	\$2,600,000	53
ME	\$980,000	17
MI	\$5,400,000	89
MN	\$2,900,000	57
MO	\$3,800,000	89
MS	\$2,200,000	55
MT	\$1,100,000	16
NC	\$7,700,000	151
ND	\$780,000	11
NE	\$870,000	22
NH	\$550,000	15
NJ	\$7,900,000	131
NM	\$640,000	15
NV	\$2,000,000	31
NY	\$7,500,000	149
OH	\$8,000,000	156
OK	\$3,800,000	78
OR	\$2,700,000	50
PA	\$9,100,000	163
PR	\$530,000	8
RI	\$440,000	8
SC	\$3,400,000	90
SD	\$430,000	13
TN	\$5,300,000	130
TX	\$24,500,000	513
UT	\$1,100,000	19
VA	\$5,900,000	126
VI	\$12,000	1
VT	\$310,000	6
WA	\$3,400,000	69
WI	\$2,800,000	43
WV	\$830,000	18
WY	\$210,000	4

Alimta®, Cyramza®, Erbitux®, Portrazza®, Retevmo® and Verzenio® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.



Other Medications		
Cialis® (tadalafil); Emgality® (galcanezumab-gnlm) injection; Evista® (raloxifene hydrochloride); Forteo® (teriparatide [rDNA origin] injection); Humatrope® (somatropin) for injection; Olumiant® (baricitinib) tablets; REYVOW® (lasmiditan); Taltz® (ixekizumab) injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$820,000	24
AL	\$14,800,000	589
AR	\$14,300,000	346
AZ	\$10,800,000	357
CA	\$33,300,000	1051
CO	\$12,800,000	395
CT	\$3,500,000	104
DC	\$110,000	5
DE	\$2,300,000	62
FL	\$70,800,000	3215
GA	\$27,900,000	996
HI	\$1,600,000	42
IA	\$5,000,000	165
ID	\$6,900,000	239
IL	\$20,500,000	619
IN	\$22,100,000	681
KS	\$8,600,000	279
KY	\$9,500,000	313
LA	\$14,800,000	471
MA	\$7,600,000	194
MD	\$5,700,000	189
ME	\$2,500,000	97
MI	\$18,200,000	556
MN	\$10,000,000	298
MO	\$20,400,000	732
MS	\$7,900,000	363
MT	\$2,700,000	100
NC	\$28,700,000	1156
ND	\$2,400,000	77
NE	\$3,500,000	136
NH	\$2,600,000	92
NJ	\$13,500,000	344
NM	\$2,200,000	64
NV	\$3,700,000	112
NY	\$17,700,000	522
OH	\$24,200,000	749
OK	\$10,600,000	376
OR	\$7,600,000	221
PA	\$21,600,000	686
PR	\$1,200,000	46
RI	\$1,200,000	43
SC	\$11,900,000	419
SD	\$2,100,000	98
TN	\$19,000,000	667
TX	\$67,600,000	2155
UT	\$6,000,000	197
VA	\$13,800,000	530
VT	\$430,000	19
WA	\$12,400,000	352
WI	\$10,400,000	352
WV	\$3,500,000	123
WY	\$730,000	27

Cialis®, Emgality®, Evista®, Forteo®, Humatrope®, Olumiant®, and Taltz® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares Foundation, Inc., Lilly Corporate Center, Indianapolis, IN 46285; Steve Stapleton, VP, stapleton_steven_j@lilly.com